Search Results for: AC Immune SA to Receive
Articles
PolTREG Receives US Patent Office Notice of Allowance for Treg Cell Therapy to Treat Type-1 Diabetes January 16, 2024
PolTREG S.A. recently announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO), covering...Sitryx Announces Collaboration Partner Lilly Has Commenced Phase 1 Study of SIT-011 for Chronic Autoimmune & Inflammatory Diseases January 4, 2024
Sitryx Therapeutics recently announced Eli Lilly & Company has commenced a Phase 1 first-in-human study of SIT-011, a post-translational modification modulator program for chronic autoimmune and….
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program January 3, 2024
Intensity Therapeutics, Inc. recently announced a business update reflecting progress in its Phase 3 sarcoma clinical program. In the fourth...GeoVax Announces Issuance of Malaria Vaccine Patent January 3, 2024
GeoVax Labs, Inc. recently announced the US Patent and Trademark Office has issued Patent No. 11,857,611 to GeoVax, pursuant to...BriaCell Reports Unprecedented Preliminary Survival & Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset December 20, 2023
BriaCell Therapeutics Corp. recently reported unprecedented preliminary survival and clinical benefit data in a new subset of advanced breast cancer...AbbVie Announces FDA & EMA Updates for Epcoritamab for the Treatment of Relapsed/Refractory Follicular Lymphoma December 11, 2023
AbbVie recently announced updates from the US FDA and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific...Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung November 29, 2023
Oxford BioTherapeutics recently announced the US FDA has granted Fast Track designation to BI 764532 for the potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of….
Dyadic Announces Top-Line Results From its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate November 29, 2023
Dyadic International, Inc. recently announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine...Biodexa Enters Agreements to Acquire Exclusive Worldwide License to a Phase 2 Ready Asset for Type 1 Diabetes November 27, 2023
Biodexa Pharmaceuticals PLC recently announced it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s rights to tolimidone (formerly coded MLR-1023) under an exclusive,….
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease With clonoSEQ Assay Across BeiGene’s Lymphoid Malignancy Pipeline November 7, 2023
Adaptive Biotechnologies Corporation recently announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ...TriSalus Life Sciences Presents Late-Breaking Phase 1 Liver Metastasis Data; Supports Development of Innovative Immuno-oncology Approach for Liver & Pancreas Indications November 6, 2023
TriSalus Life Sciences Inc. recently presented additional Phase 1 clinical data during the late-breaker oral presentation session at the Society of...Sitryx Announces Partner Eli Lilly & Company Exercises Option to SIT-011 for Chronic Autoimmune & Inflammatory Diseases November 1, 2023
Sitryx Therapeutics recently announced Eli Lilly & Company has exercised its option to progress SIT-011. Lilly will now lead further development and commercialization of the Phase 1 ready….
Pfizer & BioNTech Announce Positive Topline Data for mRNA-Based Combination Vaccine Program Against Influenza & COVID-19 October 26, 2023
Pfizer Inc. and BioNTech SE recently announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability, and immunogenicity...IMUNON Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination With Bevacizumab in Advanced Ovarian Cancer October 18, 2023
IMUNON, Inc. recently announced the first patient in a Phase 1/2 clinical trial evaluating IMNN-001 in combination with bevacizumab in...Monte Rosa Therapeutics Announces Strategic Collaboration With Roche October 17, 2023
Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEEN discovery engine with Roche’s strong expertise in delivering transformative therapies to patients….
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received US FDA Fast Track Designation for the Treatment of Extensive Stage Small Cell Lung Cancer & Extrapulmonary Neuroendocrine Cancers October 3, 2023
Oxford BioTherapeutics (OBT) recently announced the US FDA has granted Fast Track designation to BI 764532 for the treatment of...Revolo Biotherapeutics Announces Completion of Phase 1 Multiple Ascending Dose Clinical Trial of Immune-Resetting Drug Candidate September 21, 2023
Revolo Biotherapeutics recently announced the completion of a Phase 1 multiple ascending dose (MAD) clinical trial evaluating the safety and...Valneva & Pfizer Report Positive Pediatric & Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate September 7, 2023
Valneva SE and Pfizer Inc. recently announced positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, when given….
SPECIAL FEATURE - Injection Devices: Designing in Sustainability, Usability & Digitization for Patient Compliance September 5, 2023
Contributor Cindy H. Dubin, in this exclusive annual feature, highlights how leading device and drug companies are working to address the challenges of usability, sustainability, and technology to increase patient compliance.
THERAPEUTIC FOCUS - Effect of NE3107 on the Pharmacokinetics Profile of Carbidopa/Levodopa in Patients With Parkinson’s Disease September 5, 2023
Joseph M. Palumbo, MD, says addressing Parkinson’s via the inflammatory pathway offers a unique perspective that was virtually unheard of only 10 years ago.
